JP Morgan Chase
BPMC

JP Morgan Chase’s Blueprint Medicines BPMC Stock Holding History

JP Morgan Chase’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-104,000
Closed -$13.3M – 7401
2025
Q2 		$13.3M Buy
104,000
+72,300
+228% +$7.51M ﹤0.01% 2299
2025
Q1 		$2.81M Buy
+31,700
New +$3.09M ﹤0.01% 3609
2020
Q2 		– Sell
-50,600
Closed -$2.96M – 5380
2020
Q1 		$2.96M Hold
50,600
– – ﹤0.01% 2670
2019
Q4 		$4.05M Buy
+50,600
New +$3.79M ﹤0.01% 2843
2019
Q3 		– Sell
-9,900
Closed -$918K – 5731
2019
Q2 		$918K Buy
+9,900
New +$817K ﹤0.01% 3917
2018
Q4 		– Sell
-30,000
Closed -$2.34M – 5692
2018
Q3 		$2.34M Hold
30,000
– – ﹤0.01% 3345
2018
Q2 		$1.9M Buy
30,000
+3,000
+11% +$239K ﹤0.01% 3454
2018
Q1 		$2.48M Buy
+27,000
New +$2.33M ﹤0.01% 3113

Other funds holding BPMC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
VanEck Associates
VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

JP Morgan Chase's BPMC Position: Q3 2025 in Review

JP Morgan Chase sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 418,060 shares — an estimated $53.6M sold.

JP Morgan Chase first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $222M in Q1 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

  • JP Morgan Chase reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
  • JP Morgan Chase sold 418,060 Blueprint Medicines shares in Q3 2025, an estimated $53.6M.
  • JP Morgan Chase first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
  • JP Morgan Chase's Blueprint Medicines position peaked at $222M in Q1 2025.
  • 5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on JP Morgan Chase's 13F filing for Q3 2025, filed 7 Nov 2025.